As one of the most lethal diseases, pancreatic cancer shows a dismal overall prognosis and high resistance to most treatment modalities. Furthermore, pancreatic cancer escapes early detection during the curable period because early symptoms rarely emerge and specific markers for this disease have not been found. Although combinations of new drugs, multimodal therapies, and adjuvants prolong survival, most patients still relapse after surgery and eventually die. Consequently, the search for more effective treatments for pancreatic cancer is highly relevant and justified. As a newly re-discovered mediator of gasotransmission, hydrogen sulfide (H₂S) undertakes essential functions, encompassing various signaling complexes that occupy key processes in human biology. Accumulating evidence indicates that H₂S exhibits bimodal modulation of cancer development. Thus, endogenous or low levels of exogenous H₂S are thought to promote cancer, whereas high doses of exogenous H₂S suppress tumor proliferation. Similarly, inhibition of endogenous H₂S production also suppresses tumor proliferation. Accordingly, H₂S biosynthesis inhibitors and H₂S supplementation (H₂S donors) are two distinct strategies for the treatment of cancer. Unfortunately, modulation of endogenous H₂S on pancreatic cancer has not been studied so far. However, H₂S donors and their derivatives have been extensively studied as potential therapeutic agents for pancreatic cancer therapy by inhibiting cell proliferation, inducing apoptosis, arresting cell cycle, and suppressing invasion and migration through exploiting multiple signaling pathways. As far as we know, there is no review of the effects of H₂S donors on pancreatic cancer. Based on these concerns, the therapeutic effects of some H₂S donors and NO–H₂S dual donors on pancreatic cancer were summarized in this paper. Exogenous H₂S donors may be promising compounds for pancreatic cancer treatment.

胰腺癌是最致命的疾病之一，总体预后不佳，对大多数治疗方式的抵抗力很高。此外，胰腺癌在可治愈的时期内无法进行早期检测，因为早期症状很少出现并且尚未发现该疾病的特异性标志物。尽管新药，多模式疗法和佐剂的组​​合可延长生存期，但大多数患者在手术后仍会复发并最终死亡。因此，寻找更有效的胰腺癌治疗方法是高度相关和合理的。硫化氢（H ₂ S）作为一种新近发现的气体传输介质，具有重要的功能，包括占据人类生物学关键过程的各种信号复合物。越来越多的证据表明H₂ S表现出癌症发展的双峰调节。因此，内源性或低水平的外源性H ₂ S被认为会促进癌症，而高剂量的外源性H ₂ S则抑制了肿瘤的扩散。同样，抑制内源性H ₂ S的产生也抑制了肿瘤的扩散。因此，H ₂ S生物合成抑制剂和H ₂ S补充剂（H ₂ S供体）是治疗癌症的两种不同策略。不幸的是，迄今为止尚未研究内源性H ₂ S对胰腺癌的调节作用。但是，H ₂S供体及其衍生物已被广泛研究为胰腺癌治疗的潜在治疗剂，其通过利用多种信号通路抑制细胞增殖，诱导细胞凋亡，阻止细胞周期并抑制侵袭和迁移而发挥作用。据我们所知，尚无关于H ₂ S供体对胰腺癌的影响的综述。基于这些考虑，本文总结了一些H ₂ S供体和NO–H ₂ S双重供体对胰腺癌的治疗作用。外源H ₂ S供体可能是用于胰腺癌治疗的有前途的化合物。